COST-EFFECTIVENESS OF A RENAL HEALTH PROGRAM IN PATIENTS WITH HYPERTENSIVE AND/OR DIABETES INDUCED CHRONIC KIDNEY DISEASE

被引：0
|
作者：
Rosselli, D. [1 ]
DeAntonio, R. [2 ]
Calderon, C. [1 ]
Sanabria, M. [3 ]
机构：
[1] Independiente, Bogota, DC, Colombia
[2] Independent, Bogota, Colombia
[3] Baxter Colombia, Bogota, Cundinamarca, Colombia
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)74062-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A200 / A200
页数：1
相关论文
共 50 条
  • [1] Screening for chronic kidney disease with microalbumin in hypertensive patients: A cost-effectiveness analysis.
    Berbano, E
    Abbott, K
    O'Malley, P
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2004, 19 : 208 - 208
  • [2] Incremental cost-effectiveness analysis of a multidisciplinary renal education program for patients with chronic renal disease
    Sabariego, Carla
    Grill, Eva
    Brach, Mirjam
    Fritschka, Emanuel
    Mahlmeister, Jarmila
    Stucki, Gerold
    DISABILITY AND REHABILITATION, 2010, 32 (05) : 392 - 401
  • [3] Cost-effectiveness of obstructive sleep apnea screening for patients with diabetes or chronic kidney disease
    Okubo, Reiko
    Kondo, Masahide
    Hoshi, Shu-ling
    Yamagata, Kunihiro
    SLEEP AND BREATHING, 2015, 19 (03) : 1081 - 1092
  • [4] Cost-effectiveness of obstructive sleep apnea screening for patients with diabetes or chronic kidney disease
    Reiko Okubo
    Masahide Kondo
    Shu-ling Hoshi
    Kunihiro Yamagata
    Sleep and Breathing, 2015, 19 : 1081 - 1092
  • [5] Cost-effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes
    Nguyen, Bao-Ngoc
    Mital, Shweta
    Bugden, Shawn
    Nguyen, Hai V.
    DIABETES OBESITY & METABOLISM, 2023, 25 (10): : 3030 - 3039
  • [6] A COST-EFFECTIVENESS ANALYSIS OF IRBESARTAN IN THE TREATMENT OF HYPERTENSIVE PATIENTS WITH DIABETIC RENAL DISEASE
    Lee, T. J.
    Han, D. S.
    Sohn, H. S.
    VALUE IN HEALTH, 2008, 11 (06) : A503 - A503
  • [7] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN ADULT PATIENTS WITH CHRONIC KIDNEY DISEASE IN THE NETHERLANDS
    Fens, T.
    Weersma, M.
    Postma, M. J.
    Boersma, C.
    de Jong, L.
    VALUE IN HEALTH, 2023, 26 (12) : S132 - S132
  • [8] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN THE TREATMENT OF PATIENTS WITH CHRONIC KIDNEY DISEASE IN FRANCE
    Supiot, R.
    Tardu, J.
    Virely, N.
    Sivignon, M.
    Chollet, J.
    Uster, A.
    Levy, P.
    Massy, Z.
    VALUE IN HEALTH, 2024, 27 (12) : S365 - S365
  • [9] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS AFFECTED BY CHRONIC KIDNEY DISEASE IN ITALY
    Di Costanzo, A.
    Uster, A.
    Vassallo, C.
    Fiorentino, F.
    VALUE IN HEALTH, 2023, 26 (12) : S73 - S73
  • [10] Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan
    Kodera, Satoshi
    Morita, Hiroyuki
    Nishi, Hiroshi
    Takeda, Norifumi
    Ando, Jiro
    Komuro, Issei
    CIRCULATION JOURNAL, 2022, 86 (12) : 2021 - +
12345